Studies have shown cell-free microRNA(miRNA) circulating in the serum and plasma with specific expression in cancer,indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy.This study wa...Studies have shown cell-free microRNA(miRNA) circulating in the serum and plasma with specific expression in cancer,indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy.This study was to investigate whether plasma miRNA-21(miR-21) can be used as a biomarker for the early detection of non-small cell lung cancer(NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy.We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis,pathologic parameters,and treatment.Thirty-five patients(stages IIIB and IV) were evaluable for chemotherapeutic responses:11 had partial response(PR);24 had stable and progressive disease(SD+PD).Plasma miR-21 was significantly higher in NSCLC patients than in age-and sex-matched controls(P<0.001).miR-21 was related to TNM stage(P<0.001),but not related to age,sex,smoking status,histological classification,lymph node status,and metastasis(all P>0.05).This marker yielded a receiver operating characteristic(ROC) curve area of 0.775(95% CI:0.681-0.868) with 76.2% sensitivity and 70.0% specificity.Importantly,miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples(P=0.049),and were close to that in healthy controls(P=0.130).Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy.展开更多
Background Early detection and diagnosis is urgent for the sake of effective treatment strategy for lung cancer. However, a convenient, economical and relatively precise method is not available. We here report a prosp...Background Early detection and diagnosis is urgent for the sake of effective treatment strategy for lung cancer. However, a convenient, economical and relatively precise method is not available. We here report a prospective study to find the possible value of the combined use of four popular tumor markers in the early diagnosis of lung cancer among patients with suspicious nodules in the lung. Methods Six hundred and sixty inpatients with suspicious nodules in the lung were divided into a lung cancer group and a benign pulmonary tumor group according to post-operative histological examinations. Serum levels of four tumor markers including squamous cell carcinoma antigen （SCC）, carcinoembryonic antigen （CEA）, Cyfra 21-1 and neuron specific enolase （NSE） were assayed for each patient. Receiver operating characteristic （ROC） curves were constructed for each tumor marker. The power of lung cancer diagnosis of each tumor marker, as well as a combination of them were analyzed and compared. Results The serum levels （median, range） of SCC, CEA, Cyfra 21-1 and NSE were 0.44 （0.01-35.70） ng/ml, 2.49 （0.30-26.78） ng/ml, 2.30 （0.82-73.33） ng/ml and 10.54 （0.10-56.41） ng/ml respectively in lung cancer group, and were 0.32 （0.01-0.90） ng/ml, 1.60 （0.20-8.93） ng/ml, 1.41 （0.72-4.82） ng/ml and 9.36 （6.56-24.24） ng/ml respectively in the benign pulmonary tumor group. The difference in each tumor marker between the two groups was significant （P 〈0.05）. The ROCs of SCC, CEA, Cyfra 21-1 and NSE were 0.702 （95% CI, 0.654-0.751）, 0.611 （95% CI, 0.563-0.659）, 0.650 （95% Cl, 0.601-0.700） and 0.598 （95% Cl, 0.542-0.654） respectively, indicating very low power of these four tumor markers. When a combination of SCC, CEA, Cyfra 21-1 and NSE were empfoyed, the diagnosis power was strengthened. Conclusion SCC, CEA, Cyfra 21-1 and NSE are valuable in the early diagnosis of lung cancer among suspicious nodules in the lung, especially when they were assayed together for on展开更多
基金supported by grants from the National Natural Science Foundation of China(No.30772549)the Medical Sci-Tech Development Foundation from Health Department of Jiangsu Province(No.P200965)
文摘Studies have shown cell-free microRNA(miRNA) circulating in the serum and plasma with specific expression in cancer,indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy.This study was to investigate whether plasma miRNA-21(miR-21) can be used as a biomarker for the early detection of non-small cell lung cancer(NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy.We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis,pathologic parameters,and treatment.Thirty-five patients(stages IIIB and IV) were evaluable for chemotherapeutic responses:11 had partial response(PR);24 had stable and progressive disease(SD+PD).Plasma miR-21 was significantly higher in NSCLC patients than in age-and sex-matched controls(P<0.001).miR-21 was related to TNM stage(P<0.001),but not related to age,sex,smoking status,histological classification,lymph node status,and metastasis(all P>0.05).This marker yielded a receiver operating characteristic(ROC) curve area of 0.775(95% CI:0.681-0.868) with 76.2% sensitivity and 70.0% specificity.Importantly,miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples(P=0.049),and were close to that in healthy controls(P=0.130).Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy.
文摘Background Early detection and diagnosis is urgent for the sake of effective treatment strategy for lung cancer. However, a convenient, economical and relatively precise method is not available. We here report a prospective study to find the possible value of the combined use of four popular tumor markers in the early diagnosis of lung cancer among patients with suspicious nodules in the lung. Methods Six hundred and sixty inpatients with suspicious nodules in the lung were divided into a lung cancer group and a benign pulmonary tumor group according to post-operative histological examinations. Serum levels of four tumor markers including squamous cell carcinoma antigen （SCC）, carcinoembryonic antigen （CEA）, Cyfra 21-1 and neuron specific enolase （NSE） were assayed for each patient. Receiver operating characteristic （ROC） curves were constructed for each tumor marker. The power of lung cancer diagnosis of each tumor marker, as well as a combination of them were analyzed and compared. Results The serum levels （median, range） of SCC, CEA, Cyfra 21-1 and NSE were 0.44 （0.01-35.70） ng/ml, 2.49 （0.30-26.78） ng/ml, 2.30 （0.82-73.33） ng/ml and 10.54 （0.10-56.41） ng/ml respectively in lung cancer group, and were 0.32 （0.01-0.90） ng/ml, 1.60 （0.20-8.93） ng/ml, 1.41 （0.72-4.82） ng/ml and 9.36 （6.56-24.24） ng/ml respectively in the benign pulmonary tumor group. The difference in each tumor marker between the two groups was significant （P 〈0.05）. The ROCs of SCC, CEA, Cyfra 21-1 and NSE were 0.702 （95% CI, 0.654-0.751）, 0.611 （95% CI, 0.563-0.659）, 0.650 （95% Cl, 0.601-0.700） and 0.598 （95% Cl, 0.542-0.654） respectively, indicating very low power of these four tumor markers. When a combination of SCC, CEA, Cyfra 21-1 and NSE were empfoyed, the diagnosis power was strengthened. Conclusion SCC, CEA, Cyfra 21-1 and NSE are valuable in the early diagnosis of lung cancer among suspicious nodules in the lung, especially when they were assayed together for on
